Your browser doesn't support javascript.
loading
Topical dual-probe staining using quantum dot-labeled antibodies for identifying tumor biomarkers in fresh specimens.
Meng, Boyu; Folaron, Margaret R; Byrd, Brook K; Samkoe, Kimberley S; Strawbridge, Rendall S; Barth, Connor; Gibbs, Summer L; Davis, Scott C.
Afiliación
  • Meng B; Thayer School of Engineering at Dartmouth College, Hanover, New Hampshire, United States of America.
  • Folaron MR; Thayer School of Engineering at Dartmouth College, Hanover, New Hampshire, United States of America.
  • Byrd BK; Thayer School of Engineering at Dartmouth College, Hanover, New Hampshire, United States of America.
  • Samkoe KS; Geisel School of Medicine at Dartmouth College, Hanover, New Hampshire, United States of America.
  • Strawbridge RS; Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States of America.
  • Barth C; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States of America.
  • Gibbs SL; Thayer School of Engineering at Dartmouth College, Hanover, New Hampshire, United States of America.
  • Davis SC; Biomedical Engineering Department, Oregon Health and Science University, Portland, Oregon, United States of America.
PLoS One ; 15(3): e0230267, 2020.
Article en En | MEDLINE | ID: mdl-32160634
ABSTRACT

PURPOSE:

Rapid, intra-operative identification of tumor tissue in the margins of excised specimens has become an important focus in the pursuit of reducing re-excision rates, especially for breast conserving surgery. Dual-probe difference specimen imaging (DDSI) is an emerging approach that uses the difference in uptake/clearance kinetics between a pair of fluorescently-labeled stains, one targeted to a biomarker-of-interest and the other an untargeted isotype, to reveal receptor-specific images of the specimen. Previous studies using antibodies labeled with either enhanced Raman particles or organic fluorophores have shown promising tumor vs. normal diagnostic performance. Yet, the unique properties of quantum dot-labeled antibody complexes (QDACs), which provide spectrally-distinct fluorescence emission from a common excitation source, make them ideal candidates for this application. Herein, we evaluate the diagnostic performance of QDAC-based DDSI in excised xenografts. PROCEDURES Excised fresh specimens of normal tissue and human tumor xenografts with elevated expression of HER2 were stained with a HER2-targeted QDAC and an untargeted QDAC isotype. Stained specimens were imaged on a custom hyperspectral imaging system capable of spectrally separating the quantum dot signatures, and images processed using the DDSI approach. The diagnostic performance of this technique under different incubation temperatures and probe concentrations was evaluated using receiver-operator characteristic analysis.

RESULTS:

HER2-targeted QDAC-DDSI was able to distinguish HER2(+) tumors from normal tissue with reasonably high diagnostic performance; however, this performance was sensitive to temperature during the staining procedure. Area under the curve values were 0.61 when staining at room temperature but increased to over 0.81 when staining at 37 °C. Diagnostic performance was not affected by increasing stain concentration.

CONCLUSIONS:

This study is the first to report dual-probe difference imaging of specimens using QDACs and hyperspectral imaging. Our results show promising diagnostic performance under certain conditions, and compel further optimization and evaluation of this intra-operative margin assessment technique.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Puntos Cuánticos / Neoplasias Mamarias Experimentales Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Puntos Cuánticos / Neoplasias Mamarias Experimentales Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos